Opinion & analysis

L’Oréal E-Commerce Growth Approaches 50%: ‘We Are Now Clearly A Digital-First Company’

Beauty products leader L’Oréal has enjoyed much success thanks to E-commerce, the Asian market and travel retail continue to fuel gains at L’Oréal, which just posted its strongest first half like for-like growth in more than a decade. Skin care remains a key driver as well, offsetting a global slowdown in makeup that has hit the firm’s US business hardest, with little improvement expected this year. Will all this be enough to make up for sluggish conditions in North America and the US in particular, where more than half of L’Oréal’s sales are in makeup? Read the article to find out what else the company is banking on.

Get a more in-depth analysis on Pharmaceutical market trends with our Opinion on Analysis reports.

L’Oréal E-Commerce Growth Approaches 50%: ‘We Are Now Clearly A Digital-First Company’

Reckitt Invests In AI Symptom Checker To ‘Unlock Self-Care’

Sunscreen Test Lab Used Fewer Subjects Than Reported, US Prosecutors Allege

Top 20 Pharma Ranks: As Some Move Up, Others Fall Down

Made In China Gene Therapy A Father’s Quest To Save Son With UltraRare Condition

Market Intel: Needle-Free Glucose Monitoring, Digital Solutions Are Game-Changers In Growing Diabetes- Monitoring Market

Vanda Warning Letter From US FDA Leaves Firm “Puzzled”

Benefit-Risk Is Front-And-Center In Latest Revision Of International Risk Management Standard ISO 14971

Anti-Aging Cosmetics Or Unlawfully Marketed Drugs? Two Federal Court Cases To Watch

The Case For CAR-T Grows As Responses Hold Up Longer Term

Sanofi Prioritizes Cancer And Rare Diseases In Pipeline Shake-Up

Interventional Cardiology: Implantable Cardioverter Defibrillators

Innovations In Market Access: The Will, But Not The Way?

Investigator Horror Stories 3: Boozing On The Job? Yup, That Happened – As Have These Other Shocking Tales Of Irregular FDA Inspections

US FDA May Largely Avoid House Democrats’ Investigation Agenda

Testing Ranitidine with Too Much Heat Could Generate NDMA, FDA Say

Cancer Drug Combination Pricing: Genentech Offers Model For Tecentriq, Avastin

NASH: Flying The Plane While Building It

Standards, Not Predicates, Emphasized In Finalized Alternative 510(k) Pathway

Novartis’ Zolgensma Had Manipulated Data In Application, US FDA Says

Six Questions For McKinsey Executives On Pharma’s Digital Experience

From Device Centric To Disease Management: Ascensia Commits To Deeper Role In Diabetes

Patient-Specific Drive Takes Ortho Group Corin Into TKR Robotics With Omni Purchase

New Age Thinking: US FDA’s Temple Sees Third Era Of Drug Development

2018 Completed Clinical Trials: Change Is The New Constant

Analysts Weigh Up Benefits Of Big Bayer Restructuring

Two EU Notified Body Frontrunners In Race For Designation Under New Regulations

Abbott Launches New App To Keep Heart Failure Patients Out Of The Hospital

Luxturna Approved In EU: Novartis Outlines Lessons For Gene Therapy Strategies

How To Pay For The New Wave Of Gene Therapies